Amplification of the ATP-Binding Cassette 2 Transporter Gene Is Functionally Linked with Enhanced Efflux of Estramustine in Ovarian Carcinoma Cells1

Total Page:16

File Type:pdf, Size:1020Kb

Amplification of the ATP-Binding Cassette 2 Transporter Gene Is Functionally Linked with Enhanced Efflux of Estramustine in Ovarian Carcinoma Cells1 [CANCER RESEARCH 58, 1332-1337. April 1. 1998] Advances in Brief Amplification of the ATP-Binding Cassette 2 Transporter Gene Is Functionally Linked with Enhanced Efflux of Estramustine in Ovarian Carcinoma Cells1 Naomi M. Laing, Martin G. Belinsky, Gary D. Kruh, Daphne W. Bell, Jonathan T. Boyd, Linda Barone,2 Joseph R. Testa, and Kenneth D. Tew3 Departments of Pharmacology IN. M. L.. J. T. B.. L B.. K. D. T.I and Medical Oncology ¡M.C. B.. G. D. K.. D. W. B.. J. R. T.]. Fax Chase Cancer Center, Philadelphia, Pennsylvania 19111 Abstract affinity for EM (6) suggests a mechanism by which its overexpression contributes to EM resistance. We have also detected enhanced efflux An estramustine-resistant human ovarian carcinoma cell line, SKIM, of EM in an EM-resistant cell line, suggesting that increased expres was generated to explore resistance mechanisms associated with this sion of a transporter could also contribute to EM resistance. agent. Cytogenetic analysis revealed that SKEM cells have a homoge Although EM can bind to pgp and modulate its transport activity (7, neously staining region (hsr) at chromosome 9q34. Microdissection of the 8), pgp-overexpressing cells do not display cross-resistance to EM. In hsr, followed by fluorescence in situ hybridization to SKEM and normal addition, overexpression of pgp is not detected in any EM-resistant metaphase spreads, confirmed that the amplified region was derived from sequences from 9q34. In situ hybridization with a probe specific lor .I/if?, cell lines studied to date (9). These observations suggest that a a gene located at 9q34 that encodes an ATP-binding cassette 2 (ABC2) transporter distinct from pgp may contribute to EM resistance. transporter, indicated that this gene is amplified (»-foldinthe estramus To explore further EM resistance mechanisms, we characterized tine-resistant cells. Southern analysis confirmed that ABC2 was amplified SKEM in this study, an EM-resistant human ovarian carcinoma cell in SKEM, and Northern analysis indicated that the ABC2 transcript was line (SKOV3). Cytogenetic analysis revealed an hsr in this cell line overexpressed ~5-fold. The ABC1 gene located at 9q22—31was not am located at chromosome 9q34, the location of ABC2, which encodes a plified in the resistant cells, and niRNA levels of several other ABC partially characterized ABC transporter (10). Further analysis re transporter genes were unaltered. Consistent with the concept that in vealed that ABC2 is amplified and overexpressed in SKEM, that creased ABC2 expression contributes to the resistant phenotype, we ob antisense-mediated down-regulation of ABC2 expression sensitized served that the rate of efflux of dansylated estramustine was increased in SKEM compared with control cells. In addition, antisense treatment the cell line to EM, and that SKEM displays enhanced efflux of EM. directed toward ABC2 mRNA sensitized the resistant cells to estramus This study thus suggests that overexpression of ABC2 contributes to tine. Together, these results suggest that amplification and overexpression EM resistance by functioning as an efflux pump of the drug. These of ABC2 contributes to estramustine resistance and provides the first data provide the first evidence for a critical cellular role for this new indication of a potential cellular function for this product. ABC transporter family member. Introduction Materials and Methods EM,4 a conjugate of nor-nitrogen mustard and estradici, is an Development of Estramustine-resistant Cell Lines. SKOV3 ovarian car effective chemotherapeutic agent that is presently used to treat met- cinoma cells were maintained in a-MEM medium and cloned, and then one astatic, hormone-refractory prostate cancer (1). The cytotoxic activity clone was used for all subsequent experiments. Resistant cells were developed of EM relates to its ability to induce metaphase arrest by interfering by exposure to EM at concentrations starting at 1 /J.Mwith a gradual increase with microtubule structure and function (2). Biochemical studies have to 15 /¿Mover a 6-month period. The resulting SKEM cells were maintained shown that EM binds to microtubule-associated proteins and tubulin in 15 /UMEM. (3, 4), the consequence of which is depolymerization of microtubules. Chromosome Microdissection and DNA Amplification. Metaphase tu mor cells of SKEM were harvested by overnight exposure to Colcemid (0.01 To understand mechanisms associated with resistance to this agent, /¿g/ml).Metaphase spreads were prepared on 24 x 60-mm coverslips, air- we have previously characterized EM-resistant tumor cell lines and dried, and banded with trypsin-Giemsa. A single copy of the hsr was dissected studied the effects of EM on MDR cell lines. These studies demon under a Zeiss Axiovert inverted microscope with UV light-sterilized glass strated that alterations in the expression of the ß-subunitof the target needles controlled by an Eppendorf Micromanipulator 5171, as described in protein tubulin are associated with resistance to EM and other anti- detail previously (11). Briefly, needle tips containing dissected chromosomal microtubule agents. In addition, increased expression of the ßn, material were broken off directly into a 0.5-ml thin-walled Eppendorf tube. isotype of tubulin was observed in EM-resistant prostate carcinoma Microdissected DNA was PCR-amplified by the sequence-independent ampli cells (5). The subsequent observation that this isotype has reduced fication method of Bohlander et al. (12). As a positive control, 20 pg of human placenta! DNA was amplified simultaneously. A negative control without DNA template was also included. A 10-ju.l sample of each reaction was Received 12/22/97: accepted 2/16/98. visualized by ethidium bromide staining following electrophoresis through a The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 2.0% agarose gel. 18 U.S.C. Section 1734 solely to indicate this fact. Microdissection-FISH. Metaphase spreads from SKEM cells and phyto- 1This work was supported in part by N1H Grants CA06927 and RR05539. NIH Grant hemagglutin-stimulated lymphocytes from human peripheral blood were pre CA53893 (to K. D. T.), and by an appropriation from the Commonwealth of Pennsylva nia. pared according to the method of Fan et al. (13). Cultures were synchronized 2 Present address: Viro-Pharma. Malvem, PA 19355. by treatment with 5-bromodeoxyuridine (0.18 fig/ml; Sigma Chemical Co.) for 1To whom requests for reprints should be addressed, at Department of Pharmacology, 16 h, followed by release from the block by incubation in fresh medium Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia. PA !91I1. Phone: containing thymidine (2.5 jug/ml) for 6 h. Metaphase cells were harvested, and (215)728-3137; Fax: (215)728-4333. 4 The abbreviations used are: EM. estramustine; MDR. multidrug resistance: pgp, chromosome spreads were prepared according to standard procedures. P-glycoprotein: ABC, ATP-binding cassette: hsr, homogeneously staining region; FISH, A 1-jnl aliquot of the primary PCR was labeled with biotin-16-dUTP (Enzo fluorescence in xilu hybridization; DAPI. diamidino-2-phenylindole. Diagnostics) in a secondary PCR reaction (14), and 200-400 ng (5-10 ¿tl)of 1332 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 1998 American Association for Cancer Research. ABC2 GENE AMPLIFICATION AND DRUG RESISTANCE this DNA were hybridized to metaphase spreads from both SKEM cells and microscope, and the images were analyzed by ISEE analysis software (Inno- normal blood lymphocytes. vision). Excitation wavelength was 360 nm, and the emission was recorded The ABC2 probe was a 1.75-kb purified PCR product of human ABC2 with a broad spectrum emission filter. cDNA. The primers used to generate the fragment were chosen from the Daunorubicin Fluorescence. Cells on coverslips were treatedwith 10 UM sequence of an expressed sequence tag representing part of the human ABC2 daunorubicin (Sigma) for 2 h. Cells were washed and imaged after various time cDNA (EST0600) and from a 500-bp sequence from the PCR analysis of intervals using the 568-nm excitation line of a Bio-Rad MRC-600 laser ABC2 message levels. The 1.75-kB fragment was gel purified, cloned into the scanning confocal microscope. TA vector (Clontech), and sequenced. The sequence exhibited nearly >90% homology with the murine ABC2 sequence. The purified probe was labeled by Results nick translation with biotin-16-dUTP (Boehringer Mannheim) and mapped to ABC2 Is Amplified in the EM-resistant Cell Line. EM-resistant normal human chromosomes. FISH and detection of immunofluorescence were carried out essentially as ovarian carcinoma cells were generated by exposing sensitive cells to described previously (15). Biotinylated probes were denatured, preannealed gradually increasing concentrations of the drug. The resulting cells with excess Cot-1 DNA, and hybridized overnight at 37°Cto metaphase (designated SKEM) exhibited a 5-6-fold level of resistance to EM spreads on a 24 x 60-mm slide. Hybridization sites were detected with compared with the SKOV3 parental cells. Because drug-resistant cells fluorescein-labeled avidin (Oncor) and amplified by the addition of anti-avidin often display newly acquired chromosomal abnormalities, karyotypic antibody (Oncor) and a second layer of fluorescein-labeled avidin. The chro analysis of parental SKOV3 and SKEM cells was performed. The mosome preparations were counterstained with DAPI and observed with a Giemsa-banded metaphase chromosomes from SKEM cells showed Zeiss Axiophot epifluorescence microscope equipped with a cooled charge the presence of an abnormal chromosome 9 not present in the parental coupled device camera (Photometries, Tucson AZ) operated by a Macintosh cells. This aberrant chromosome 9 contained an hsr located at band computer work station. Digitized images of DAPI staining and fluorescein signals were captured, pseudo-colored, and merged using Oncor version 1.6 9q34 (Fig. la). We used chromosome microdissection techniques to software. characterize the amplicon of the hsr.
Recommended publications
  • WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT (51) International Patent Classification: A61K 31/53 (2006 .01) A61P 35/00 (2006 .0 1) C07D 251/40 (2006.01) (21) International Application Number: PCT/US20 18/024 134 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/476,585 24 March 2017 (24.03.2017) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US). (72) Inventors: NOMURA, Daniel, K.; 4532 Devenport Av enue, Berkeley, CA 94619 (US). ANDERSON, Kimberly, E.; 8 Marchant Court, Kensington, CA 94707 (US). (74) Agent: LEE, Joohee et al; Mintz Levin Cohn Ferris Glovsky And Popeo, P.C., One Financial Center, Boston, MA 021 11 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Recent Advances in the Management of Hormone Refractory Prostate Cancer
    Korean J Uro-Oncol 2004;2(3):147-153 Recent Advances in the Management of Hormone Refractory Prostate Cancer Mari Nakabayashi, William K. Oh Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA A typical treatment strategy after AAWD is to use secondary INTRODUCTION hormonal manipulations, although studies have not yet demonstrated a survival benefit with this class of treatment. Prostate cancer is the most common cancer in men in the Options in this category include (1) the secondary use of anti- United States and accounted for 29,900 deaths in 2003.1 androgens (e.g., high-dose bicalutamide, nilutamide), (2) thera- Although most men with advanced prostate cancer respond pies targeted against adrenal steroid synthesis (e.g., ketocona- initially to androgen deprivation therapies (ADT) by either zole, corticosteroids), and (3) estrogenic therapies (e.g. diethy- bilateral orchiectomy or leuteinizing hormone releasing hor- lstilbestrol). Symptomatic improvement and PSA responses mone (LHRH) analogues, patients eventually progress to an (defined as PSA decline >50% after treatment) have been androgen-independent state in which the initial ADT no longer reported in approximately 20% to 80% of patients with is adequate to control disease.2 Progression of the disease hormone-refractory prostate cancer (HRPC) with a typical manifests as an increase in serum prostate-specific antigen duration of response of 2 to 6 months. Toxicity is generally (PSA) or may be accompanied by radiographic evidence of mild for these oral therapies, although serious side effects, tumor growth. Here we report a brief summary of recent including adrenal insufficiency, liver toxicity, and thrombosis, advances in the management of hormone refractory prostate may occur (Table 1).
    [Show full text]
  • Cumulative Cross Index to Iarc Monographs
    PERSONAL HABITS AND INDOOR COMBUSTIONS volume 100 e A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 29 September-6 October 2009 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS The volume, page and year of publication are given. References to corrigenda are given in parentheses. A A-α-C .............................................................40, 245 (1986); Suppl. 7, 56 (1987) Acenaphthene ........................................................................92, 35 (2010) Acepyrene ............................................................................92, 35 (2010) Acetaldehyde ........................36, 101 (1985) (corr. 42, 263); Suppl. 7, 77 (1987); 71, 319 (1999) Acetaldehyde associated with the consumption of alcoholic beverages ..............100E, 377 (2012) Acetaldehyde formylmethylhydrazone (see Gyromitrin) Acetamide .................................... 7, 197 (1974); Suppl. 7, 56, 389 (1987); 71, 1211 (1999) Acetaminophen (see Paracetamol) Aciclovir ..............................................................................76, 47 (2000) Acid mists (see Sulfuric acid and other strong inorganic acids, occupational exposures to mists and vapours from) Acridine orange ...................................................16, 145 (1978); Suppl. 7, 56 (1987) Acriflavinium chloride ..............................................13,
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317850 A1 Hewitt Et Al
    US 20080317850A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317850 A1 Hewitt et al. (43) Pub. Date: Dec. 25, 2008 (54) BUCCAL DELIVERY SYSTEM Publication Classification (51) Int. Cl. (76) Inventors: Ernest Alan Hewitt, New South A69/20 (2006.01) Wales (AU); Richard James A6II 47/34 (2006.01) Stenlake, New South Wales (AU) A 6LX 3/57 (2006.01) A6II 3/565 (2006.01) Correspondence Address: A6II 3/568 (2006.01) REED SMITH LLP A6II 3/66 (2006.01) P.O. BOX 488 (52) U.S. Cl. ......... 424/464; 424/486; 514/177: 514/182: PITTSBURGH, PA 15230-0488 (US) 514/178; 514/108 (57) ABSTRACT (21) Appl. No.: 11/910,902 A buccal delivery system capable of being blended in a nor 1-1. mal dry powder process and compressed using a standard (22) PCT Filed: Apr. 7, 2006 tabletting machine, said buccal delivery system comprising a matrix of: (a) an effective amount of one or more active (86). PCT No.: PCT/AU2OO6/OOO472 ingredients; (b) an amount of one or more polyethylene gly cols orderivatives thereofhaving a molecular weight between S371 (c)(1), 1000 to 8000 sufficient to provide the required hardness and (2), (4) Date: Feb. 5, 2008 time for dissolution of the matrix; (c) 0.05-2% by weight of the total matrix of one or more Suspending agents; (d) 0.05 (30) Foreign Application Priority Data 2% by weight of the total matrix of one or more flowing agents; and (e) 0.05-2% by weight of the total matrix of one or Apr.
    [Show full text]
  • Meo Meo C Meo US 6,794,384 B1 Page 2
    USOO6794384B1 (12) United States Patent (10) Patent No.: US 6,794,384 B1 Potter et al. (45) Date of Patent: Sep. 21, 2004 (54) HYDROXYLATION ACTIVATED DRUG 6,214,886 B1 4/2001 Potter et al. ................ 514/685 RELEASE 6,346,550 B2 2/2002 Potter et al. ...... ... 514/685 2002/0037296 A1 3/2002 Potter et al. ................ 424/400 (75) Inventors: Gerard Andrew Potter, Leicester (GB); Lawrence Hylton Patterson, FOREIGN PATENT DOCUMENTS Leicester (GB); Michael Danny Burke, CA 2109259 4/1994 Leicester (GB) DE 4309344 9/1949 DE 4236237 4/1994 (73) Assignee: De Montfort University, Leicester EP O322 738 A2 7/1989 EP O642799 3/1995 (GB) JP 56/O16474 A2 * 2/1981 JP 56O16474 2/1981 ......... CO7D/239/54 (*) Notice: Subject to any disclaimer, the term of this JP 61076433 4/1986 patent is extended or adjusted under 35 JP O81885.46 7/1996 U.S.C. 154(b) by 0 days. WO 971.2246 4/1997 WO WO 99/40056 8/1999 (21) Appl. No.: 09/633,697 WO WO 99/40944 8/1999 (22) Filed: Aug. 7, 2000 OTHER PUBLICATIONS Draetta, G. and Pagano, M. in “Annual Reports in Medicinal Related U.S. Application Data Chemistry, vol. 31, 1996, Academic Press, San Diego, p (63) Continuation of application No. PCT/GB99/00416, filed on 241-248. Feb. 10, 1999. Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975–977.* (30) Foreign Application Priority Data Banker, G.S. et al., “Modern Pharmaceutics, 3ed.'', Marcel Feb. 12, 1998 (GB) ............................................. 98O2957 Dekker, New York, 1996, p.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,265,147 B1 Mobley Et Al
    USOO6265147B1 (12) United States Patent (10) Patent No.: US 6,265,147 B1 Mobley et al. (45) Date of Patent: Jul. 24, 2001 (54) METHOD OF SCREENING FOR Carmeci, Charles, et al., “Identification of a Gene (GPR30) NEUROPROTECTIVE AGENTS with Homology to the G-Protein-Coupled Receptor Super family ASSociated with Estrogen Receptor Expression in (75) Inventors: William C. Mobley, Palo Alto; Ronald Breast Cancer,” Genomics (1997) vol. 45:607-617. J. Weigel, Woodside; Chengbiao Wu, Owman, Christer, et al., “Cloning of Human cDNA Encod San Jose; Har Hiu Dawn Lam, ing a Novel Hepathelix Receptor Expressed in Burkitt's Stanford, all of CA (US) Lymphoma and Widely Distributed in Brain abd Peripheral Tissues,” Biochemical and Biophysical Research Cimmuni (73) Assignee: The Board of Trustees of the Leland cations (1996) vol. 228:285–292. Stanford Junior University, Palo Alto, Singh, Meharvan, et al., “Estrogen-Induced Activation of CA (US) Mitogen-Activated Protein Kinase in Cerebral Cortical Explants: Convergence of Estrogen and Neurotrophin Sig (*) Notice: Subject to any disclaimer, the term of this naling Pathways,” Journal of Neuroscience (Feb. 15, 1999) patent is extended or adjusted under 35 vol. 19(4): 1179–1188. U.S.C. 154(b) by 0 days. Toran-Allerand, C. Dominique, “The Estrogen/Neurotro phin Connection During Neural Development: Is Co-Lo (21) Appl. No.: 09/452,531 calization of Estrogen Receptors with the Neurotrophins and Their Receptors Biologically Revelant?”, Dev: Neurosci. (22) Filed: Dec. 1, 1999 (1996) vol. 18:36–48. (51) Int. Cl." ................................................... C12O 1/00 Genbank Accession Number Y08162. (52) U.S. Cl. ............................... 435/4; 435/69.1; 514/169 * cited by examiner (58) Field of Search ........................
    [Show full text]
  • Estramustine Phosphate Inhibits Germinal Vesicle Breakdown and Induces Depolymerization of Microtubules in Mouse Oocyte Hélène Rime, Catherine Jessus, R
    Estramustine phosphate inhibits germinal vesicle breakdown and induces depolymerization of microtubules in mouse oocyte Hélène Rime, Catherine Jessus, R. Ozon To cite this version: Hélène Rime, Catherine Jessus, R. Ozon. Estramustine phosphate inhibits germinal vesicle breakdown and induces depolymerization of microtubules in mouse oocyte. Reproduction Nutrition Développe- ment, 1988, 28 (2A), pp.319-334. hal-00898793 HAL Id: hal-00898793 https://hal.archives-ouvertes.fr/hal-00898793 Submitted on 1 Jan 1988 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Estramustine phosphate inhibits germinal vesicle breakdown and induces depolymerization of microtubules in mouse oocyte Hélène RIME Catherine JESSUS R. OZON Laboratoire de Physiologie de la Reproduction, Groupe Stéroides, UA-CNRS 555, Université Pierre et Marie Curie, 4, place Jussieu, 75252 Paris Cedex 05, France. Summary. The first meiotic cell division (meiotic maturation) of the dictyate stage of mouse oocytes, removed from the follicle, resumes spontaneously in vitro. This study indicates that estramustine phosphate reversibly blocks meiotic maturation by inhibiting germinal vesicle breakdown. Oocyte cryostat sections were stained with anti-tubulin and two antibodies (anti-MAP1 : JA2 and 5051) which decorated the metaphase spindle during meiotic maturation.
    [Show full text]
  • Effects of Cancer Chemotherapeutic Agents on Endocrine Organs and Serum Levels of Estrogens, Progesterone, Prolactin, and Luteinizing Hormone'
    [CANCER RESEARCH 35, 1975-1980, August 1975] Effects of Cancer Chemotherapeutic Agents on Endocrine Organs and Serum Levels of Estrogens, Progesterone, Prolactin, and Luteinizing Hormone' Eric V. H. Kuo, Henry J. Esber, D. Jane Taylor, and Arthur E. Bogden Department oflmmunobiology, Mason ResearchInstitute, Worcester,Massachusetts01608[E. Y. H. K., H. J. E., A. E. B.], and Division of Cancer Biology and Diagnosis,National CancerInstitute, Bethesda,Maryland 21.Xfl4[D.J. T.] SUMMARY INTRODUCTION The effects of the following cancer chemotherapeutic Many types ofneoplasms, both spontaneous and induced, agents on serum hormonal levels, estrous cycles, and are known to arise in the various endocrine organs as well as endocrine organs were studied in mature, normal in the target tissues of hormones. The growth of tumors Sprague-Dawley rats by radioimmunoassay, vaginal smear arising in endocrine-responsive tissues is frequently found to examination, and organ weight end point: estradiol mustard be hormone dependent or at least hormone responsive. (NSC 112259), testosterone mustard (NSC I 12260), phen Recent studies (9, 11) on gs antigen expression have estrin (NSC 104469), methotrexate (NSC 740), 5-fluo produced evidence suggesting that certain hormones may rouracil (NSC 19893), vinblastine (NSC 49842), vincristine also play a role in activating the oncogenic expression of (NSC 67574), nitrogen mustard (NSC 762), and l,3-bis(2- some RNA tumor virus genomes. While hormonal effects chloroethyl)-l-nitrosourea (NSC 409962). Following 2 are often associated with stimulation of tumor growth, an weeks of treatment, estradiol-17fi levels were markedly inhibitory effect on tumor growth may also be exerted by elevated by all compounds except testosterone mustard and hormones (14, 24).
    [Show full text]
  • Report Versionpdf
    THIRD EDITION 2004 Stateof the Evidence What Is the Connection Between the Environment and Breast Cancer? Edited by Nancy Evans, Health Science Consultant, Breast Cancer Fund Dedicated to our founders, pioneers in breast cancer and environmental health ANDREA RAVINETT MARTIN 1946-2003 Breast Cancer Fund ELENORE G. PRED 1933-1991 Breast Cancer Action Cover Illustration: Book of Flowers IX, by Lynda Fishbourne, 1997, “Art.Rage.Us; Art and Writing by Women with Breast Cancer” After I finished chemotherapy and started radiation treatments every day, I also found a new medium, encaustic (wax). It felt like a rebirth in a way. As a reward to myself for my daily hospitals visits, I painted in encaustic every day before leaving for my appointment. A series of these paintings resulted. The darker side has petals falling, and the background is etched with counting; it shows what I was leaving behind. The lighter, sunnier side contains written thoughts as well as flowers and leaves from my walks in nature. It reflects the more positive feelings I was having. Acknowledgments Breast Cancer Fund and Breast Cancer Action wish to thank the following scientific experts who reviewed and commented on State of the Evidence: Devra Lee Davis, Ph.D., M.P.H., Director, Center for Environmental Oncology, University of Pittsburgh Cancer Institute and Professor, Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh. Philip Randolph Lee, M.D., Professor Emeritus, University of California San Francisco School of Medicine, former Assistant Secretary of Health & Human Services, San Francisco, Calif. Annie J. Sasco, M.D., Dr P.H., Chief of the Unit of Epidemiology for Cancer Prevention, International Agency for Research on Cancer and Director of Research, Institut National de la Santé et de la Recherche Médicale, Lyon, France.
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al
    US 2002001 0208A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua et al. (43) Pub. Date: Jan. 24, 2002 (54) DHA-PHARMACEUTICAL AGENT Related U.S. Application Data CONJUGATES OF TAXANES (63) Continuation of application No. 09/135,291, filed on (76) Inventors: Victor Shashoua, Brookline, MA (US); Aug. 17, 1998, now abandoned, which is a continu Charles Swindell, Merion, PA (US); ation of application No. 08/651,312, filed on May 22, Nigel Webb, Bryn Mawr, PA (US); 1996, now Pat. No. 5,795,909. Matthews Bradley, Layton, PA (US) Publication Classification Correspondence Address: Edward R. Gates, Esq. (51) Int. Cl." ............................................ A61K 31/337 Wolf, Greenfield & Sacks, P.C. (52) U.S. Cl. .............................................................. 514/449 600 Atlantic Avenue Boston, MA 02210 (US) (57) ABSTRACT The invention provides conjugates of cis-docosahexaenoic (21) Appl. No.: 09/846,838 acid and pharmaceutical agents useful in treating noncentral nervous System conditions. Methods for Selectively target 22) Filled: Mayy 1, 2001 ingg pharmaceuticalp agents9. to desired tissues are pprovided. Patent Application Publication Jan. 24, 2002 Sheet 1 of 14 US 2002/0010208A1 1 OO 5 O -5OO - 1 OO-9 -8 -7 -6 -5 -4 LOG-10 OF SAMPLE CONCENTRATION (MOLAR) CCRF-CEM-o- SR ----- RPM-8226----- K-562- - -A - - HL-60 (TB) -g- - MOLT4: ... O Fig. 1 1 OO 5 O -5OO -1 O O -8 -7 -6 -5 -4 -- 9 LOGo OF SAMPLE CONCENTRATION (MOLAR) A549/ATCC-o-NS326. NCEKVX 28. --Q-- NCI-H322M-...-a---Eidsf8::... NC-H522--O-- HOP-62---Fig. 2 a-- NC-H460.-------- Patent Application Publication Jan.
    [Show full text]
  • ADT) Plus Chemotherapy As Initial Treatment for Local Failures Or Advanced Prostate Cancer
    Phase 2 Study of Androgen Deprivation Therapy (ADT) plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer NCT02560051 Version Date: 01/26/2016 IRB NUMBER: HSC-MS-14-0949 IRB APPROVAL DATE: 01/26/2016 Androgen Deprivation Therapy (ADT) plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer Clinical Protocol No: GU-13-101 Principal Investigator: Robert J. Amato, D.O. Director and Professor, Department of Internal Medicine, Division of Oncology 6410 Fannin, Suite 830 Houston, TX 77030 832-725-7702 Collaborators: Varaha Tammisetti, M.D. Angel Blanco, M.D. Nwabugwu S. Ochuwa, Pharm.D., BCOP Reynolds Brobey, Ph.D. Statistician: Jessica Williams, M.S. Center: Memorial Hermann Cancer Center Version 1: February 20, 2015 Version 2: October 1, 2015 Version 3: November 20, 2015 Version 4: January 13, 2016 The study is to be conducted according to the protocol and in compliance with Good Clinical Practice (GCP) and other applicable regulatory requirements. Signature: Date: Robert J. Amato, D.O. IRB NUMBER: HSC-MS-14-0949 IRB APPROVAL DATE: 01/26/2016 Confidential Page 2 of 57 Protocol No. GU-13-101 Ver. 4, dated 01/13/2016 TABLE OF CONTENTS PROTOCOL SYNOPSIS ...........................................................................................................................................4 1.0 OBJECTIVES.................................................................................................................................................9 2.0 BACKGROUND ............................................................................................................................................9
    [Show full text]